Main Article Content
Abstract
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the world. Four new oral anticoagulants have become available as alternatives for warfarin in patients with AF. Although the newer aspects have higher acquisition cost, the benefits of cost savings may be derived from potential for decreasing the bleeding incidence and reducing the need for anticoagulation monitoring.
Keywords
Atrial fibrillation
anticoagulants
Article Details
License
Authors who publish in the Jurnal Kedokteran dan Kesehatan Indonesia agree to the following terms:
- Authors retain copyright and grant Jurnal Kedokteran dan Kesehatan Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution Licence that allows others to adapt (remix, transform, and build) upon the work non-commercially with an acknowledgement of the work's authorship and initial publication in Jurnal Kedokteran dan Kesehatan Indonesia.
- Authors are permitted to share (copy and redistribute) the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Jurnal Kedokteran dan Kesehatan Indonesia.
How to Cite
Yakobus, Y. (2017). New oral anticoagulants for atrial fibrillation. JKKI : Jurnal Kedokteran Dan Kesehatan Indonesia, 8(2), 102–109. https://doi.org/10.20885/JKKI.Vol8.Iss2.art5